D.E. Shaw & Co
RYTM icon

D.E. Shaw & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

D.E. Shaw & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.84M Buy
32,652
+1,296
+4% +$126K ﹤0.01% 2638
2025
Q4 		$3.36M Buy
31,356
+27,771
+775% +$2.95M ﹤0.01% 2642
2025
Q3 		$362K Sell
3,585
-20,693
-85% -$1.92M ﹤0.01% 4021
2025
Q2 		$1.53M Sell
24,278
-59,591
-71% -$3.65M ﹤0.01% 2930
2025
Q1 		$4.44M Buy
83,869
+35,671
+74% +$1.98M ﹤0.01% 1983
2024
Q4 		$2.7M Buy
48,198
+43,904
+1,022% +$2.43M ﹤0.01% 2495
2024
Q3 		$225K Buy
+4,294
New +$206K ﹤0.01% 4107
2024
Q2 		– Sell
-10,462
Closed -$453K – 4801
2024
Q1 		$453K Sell
10,462
-118,030
-92% -$5.17M ﹤0.01% 3538
2023
Q4 		$5.91M Buy
+128,492
New +$4.05M 0.01% 1780
2023
Q2 		– Sell
-278,203
Closed -$4.96M – 4509
2023
Q1 		$4.96M Sell
278,203
-77,327
-22% -$1.94M 0.01% 1944
2022
Q4 		$10.4M Buy
355,530
+172,461
+94% +$4.43M 0.01% 1396
2022
Q3 		$4.49M Buy
183,069
+146,577
+402% +$2.73M 0.01% 2223
2022
Q2 		$151K Sell
36,492
-60,493
-62% -$331K ﹤0.01% 4637
2022
Q1 		$1.12M Buy
+96,985
New +$851K ﹤0.01% 3824
2021
Q2 		– Sell
-31,653
Closed -$673K – 4983
2021
Q1 		$673K Buy
+31,653
New +$918K ﹤0.01% 3364
2019
Q1 		– Sell
-10,982
Closed -$295K – 3878
2018
Q4 		$295K Sell
10,982
-41,179
-79% -$1.14M ﹤0.01% 3356
2018
Q3 		$1.52M Buy
52,161
+14,586
+39% +$461K ﹤0.01% 2391
2018
Q2 		$1.18M Buy
+37,575
New +$1.03M ﹤0.01% 2606

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

D.E. Shaw & Co's RYTM Position: Q1 2026 in Review

D.E. Shaw & Co increased its Rhythm Pharmaceuticals (RYTM) stake by 4.1% in Q1 2026, buying an estimated $126K and bringing the position to 32,652 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

D.E. Shaw & Co first reported a position in RYTM in Q2 2018 and has held it in 18 quarters since. The position peaked at $10.4M in Q4 2022. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • D.E. Shaw & Co held 32,652 shares of Rhythm Pharmaceuticals worth $2.84M as of Q1 2026.
  • D.E. Shaw & Co bought 1,296 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $126K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2638 holding.
  • D.E. Shaw & Co first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.